Peptides DB
Research-centric peptide and protocol reference hub
Study 11 of 11Efpeglenatide literatureCurrent medical research and opinion · Observational2026

Disease burden among patients with generalized myasthenia gravis in the United States receiving standard of care therapy: the patient perspective.

Patients with generalized myasthenia gravis receiving standard care report significant disease burden and impaired quality of life, especially those with moderate to severe symptoms.

Read at Current medical research and opinionAdd to compare

Where it sits

this study against the rest of the efpeglenatide corpus
1
Preclinical
7
Observational · this one
0
Open-label
1
Randomised
2
Reviews

Summary and findings

This study examined the disease burden in patients with generalized myasthenia gravis (gMG) receiving standard of care therapy. A total of 157 patients completed an online survey, revealing various quality of life metrics. Patients with moderate/severe gMG reported greater impairment compared to those with mild gMG.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
gMG severity was associated with severity of health-related quality of life impairment (coefficient 0.103 [95% CI 0.043, 0.191]).n=1572026

Abstract

The authors’ words, as Current medical research and opinion supplied them

<h4>Objective</h4>Examination of disease burden experienced by patients with gMG treated with standard of care and not with advanced biologics can inform treatment decision-making.<h4>Methods</h4>A cross-sectional, online survey was completed by adults with generalized myasthenia gravis (gMG; patients self-reported a confirmed diagnosis) in the United States. Patients had received treatment with standard of care (acetylcholinesterase inhibitors, non-steroidal immunosuppressants, corticosteroids, rituximab, immunoglobulins, plasmapheresis) but not advanced biologics (eculizumab, ravulizumab, zilucoplan, efgartigimod, rozanolixizumab, nipocalimab). Responses were compared between patients with mild or moderate/severe gMG (Myasthenia Gravis Activites of Daily Living [MG-ADL] score 0-4 or 5-24). Linear elastic-net regression analysis explored associations between MG-ADL score and selected variables.<h4>Results</h4>Overall, 157 eligible patients completed the survey (87.3% female, mean [SD] age 49.5 [14.4] years, mean [SD] time since diagnosis 11.0 [10.9] years). Mean (SD) MG-QoL-15R score was 16.2 (7.2), EQ5D-5L score was 0.6 (0.3), and FACIT-fatigue subscale score was 20.2 (11.3). Overall, 51.6% received additional support/care. Patients with moderate/severe gMG (136/157 [86.6%]) had greater symptom occurence, reduced treatment satisfaction, greater health-related quality of life impairment, and greater support/care needs, compared with patients with mild gMG. In a regression analysis, gMG severity was associated with severity of health-related quality of life impairment (as measured by MG-ADL score and MG-QOL-15R score; coefficient 0.103 [95% CI 0.043, 0.191]).<h4>Conclusion</h4>Patients in the United States with gMG who are receiving only standard of care report a significant disease burden and impaired quality of life, with greater impairment among patients with severe gMG.

Background

This paper addresses the disease burden experienced by patients with generalized myasthenia gravis (gMG) who are treated with standard care therapies. Prior research has indicated that gMG can significantly impact quality of life, but the specific experiences of patients receiving only standard treatments have not been thoroughly documented. Understanding these burdens can inform treatment decision-making and highlight areas for potential improvement in patient care.

Methods

A cross-sectional, online survey was conducted among adults with confirmed gMG in the United States. The study included 157 eligible patients who had received standard of care treatments but not advanced biologics. The primary outcome measures included the Myasthenia Gravis Activities of Daily Living (MG-ADL) score and the MG-QoL-15R score, with linear elastic-net regression analysis used to explore associations.

Results

The mean (SD) age of participants was 49.5 (14.4) years, with a mean (SD) time since diagnosis of 11.0 (10.9) years. Patients with moderate/severe gMG (136/157 [86.6%]) reported greater symptom occurrence, reduced treatment satisfaction, and greater health-related quality of life impairment compared to those with mild gMG. The regression analysis indicated that gMG severity was associated with health-related quality of life impairment, with a coefficient of 0.103 (95% CI 0.043, 0.191).

Interpretation

The findings suggest that patients with moderate/severe gMG experience a more significant disease burden compared to those with mild gMG, which aligns with existing literature on the impact of disease severity on quality of life. However, the effect size reported (coefficient 0.103) may be considered small, indicating that while statistically significant, the clinical relevance may be limited. The study's reliance on self-reported data and its cross-sectional design are notable confounds that could affect the reliability of the conclusions drawn.

Key findings

  • Mean (SD) MG-QoL-15R score was 16.2 (7.2).
  • EQ5D-5L score was 0.6 (0.3).
  • FACIT-fatigue subscale score was 20.2 (11.3).
  • 51.6% received additional support/care.
  • gMG severity was associated with severity of health-related quality of life impairment (coefficient 0.103 [95% CI 0.043, 0.191]).

Limitations

  • Self-reported data may introduce bias.
  • Cross-sectional design limits causal inferences.
  • Small sample size may not represent the broader population.
  • No comparison with patients receiving advanced biologics.

Elsewhere in the Efpeglenatide corpus

CPharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity, inflammation, and fibrosis in the antitopoisomerase-I antibody-driven mouse model of systemic sclerosis.Annals of the rheumatic diseases · 2026 · Not reported in abstract.AnimalASafety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis.Brain and behavior · 2023 · n=480 · MD = -4.59 for QMG scores, 95% CI: -6.24 to -2.94, p < 0.00001.reviewBA Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast-Acting Treatment for Impeding Crisis of MuSK-MG.Immunity, inflammation and disease · 2023 · n=1 · QMG score improved from 31 to 23 after the first efgartigimod infusion.HumanBImmune checkpoint inhibitor-induced myocarditis with myositis and/or myasthenia gravis overlap syndrome: A case series.Experimental and therapeutic medicine · 2026 · n=6 · Median age 70.5 years (range, 63-83 years).HumanBPerioperative Administration of Efgartigimod in myasthenia gravis patients with Thymoma: A six-case series.Journal of neuroimmunology · 2026 · n=6 · Not reported in abstract.HumanBDurable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP.Platelets · 2026 · n=1 · Not reported in abstract.Human